All In Biotech

Drug Trial Radar · NCT02962414

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

206

Actual

Start

Aug 23, 2017

Primary completion

Feb 26, 2027

Study completion Feb 26, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be benefiting from continued treatment as judged by the investigator at the completion of EXIST-3

Conditions

  • Tuberous Sclerosis Complex

Interventions

  • everolimusDrug

    everolimus, 2mg dispersible tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurances of adverse events and serious adverse eventsTime frame: Day 1 up to approximately 10 years

Locations

68 sites in 18 countries. Site status is shown where the registry gives one.

  • TGen APNNA

    Phoenix, Arizona

  • David Geffen School of Medicine at UCLA

    Los Angeles, California

  • UCSF Benioff Children s Hospital

    Oakland, California

  • Rady Children s Hospital

    San Diego, California

  • University of Colorado School of Medicine

    Aurora, Colorado

  • Connecticut Childrens Medical Cntr

    Hartford, Connecticut

  • University of Chicago Medical Center

    Chicago, Illinois

  • Minnesota Epilepsy Group

    Saint Paul, Minnesota

  • Atlantic Health Morristown MC

    Morristown, New Jersey

  • Cinn Children Hosp Medical Center

    Cincinnati, Ohio

  • Oregon Health Sciences University

    Portland, Oregon

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Texas Scottish Rite Hos for Child

    Dallas, Texas

  • Texas Childrens Hospital

    Houston, Texas

  • Novartis Investigative Site

    Sydney, New South Wales, Australia

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site

    Amiens, France

  • Novartis Investigative Site

    Bron, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Bari, BA, Italy

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Pavia, PV, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Siena, SI, Italy

  • Novartis Investigative Site

    Okayama, Japan

  • Novartis Investigative Site

    Osaka, Osaka, Japan

  • Novartis Investigative Site

    Suita, Osaka, Japan

  • Novartis Investigative Site

    Shizuoka, Shizuoka, Japan

  • Novartis Investigative Site

    Guadalajara, Jalisco, Mexico

  • Novartis Investigative Site

    Warsaw, Poland

  • Novartis Investigative Site

    Moscow, Russia

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.